Cannon Advisors, Inc. Sangamo Therapeutics, Inc Transaction History
Cannon Advisors, Inc.
- $142 Billion
- Q4 2025
A detailed history of Cannon Advisors, Inc. transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Cannon Advisors, Inc. holds 11,750 shares of SGMO stock, worth $5,170. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,750Holding current value
$5,170% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SGMO
# of Institutions
124Shares Held
62.2MCall Options Held
953KPut Options Held
1.11M-
Vanguard Group Inc Valley Forge, PA11.6MShares$5.11 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny10.2MShares$4.48 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$2.07 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X03.66MShares$1.61 Million0.21% of portfolio
-
Geode Capital Management, LLC Boston, MA3.29MShares$1.45 Million0.0% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $68.9M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...